ObjectiveTo systematically review studies on evaluating the quality evaluation index and the transformation application effect evaluation index of domestic related scientific and technological achievements, to analyze and identify the key elements of evaluating the " production-transformation” of scientific and technological achievements, and to provide the methodological support for the establishment of evaluation system for the transformation and application of domestic scientific and technological achievements.MethodsWe searched CNKI, WanFang Data, SinoMed and VIP databases from inception to December 2016. In addition, manual retrieval and tracing references were also used to collect researches. Two reviewers screened literatures, extracted data, and descriptive analysis was performed to assess the results.ResultsA total of 18 studies on the production quality of the technological achievements and 12 studies on the transformation and application effect of the technological achievements were included. The results of systematic reviews showed that: the evaluation of production quality of technological achievements were mainly established from the benefits, characteristics, value, effect and source, and input of technological achievements; the evaluation of transformation and application of technological achievements were mainly established from researching and development ability, transforming ability and transformation effect of technological achievements.ConclusionsThe evaluation of technological achievements covers 2 key links: the production quality, transformation and application effect of technological achievements that are mutually complementary to each other. At the same time, the value elements are found in the production quality, transformation and application of technological achievements, namely scientific value, discipline value, economic value and social value. Therefore it is necessary to establish the evaluation of production quality, transformation and application effect of technological achievements based on the value.
ObjectiveTo investigate the development, production and use of children’s drugs in Sichuan Province, analyze the problems existing in these links, and provide suggestions for ensuring that children’s needs for drugs are met. MethodsThe self-filling electronic questionnaire was used to investigate the production, procurement and use of children’s drugs in 14 pharmaceutical companies producing children’s drugs and 20 general hospitals with pediatric departments or children’s hospitals in Sichuan province. ResultsThe 14 surveyed pharmaceutical companies reported that 116 children’s drugs were being developed or produced (75 first-class children’s drugs with exact medication information for children, 41 second-class children’s drugs only noted as children's discretionary reduction or use according to clinician’s instructions), out of which 109 (93.97%) drugs had been approved for marketing, 21 (18.10%) were national essential medicines and 76 (65.52%) were covered by national basic medical insurance. The dosage forms of first-class children's drugs were mainly tablets (28, 37.34%) and granules (19, 25.34%), while oral solution (3, 4.00%), syrup (5, 6.67%) and other dosage forms suitable for children were less. According to the surveyed results on the use of children's drugs in hospitals, there were 57 children’s drugs whose minimum use units needed to be manually divided into smaller ones on average in each hospital, and it was the most common operation pattern that pharmacists informed nurses, patients or patients’ family members of the dose splitting methods and then splitting drugs’ minimum use units by themselves. ConclusionThere is a great demand for splitting minimum use units of drugs whose strength is too big for children in medical institutions, and some children’s drugs need to be developed and further modified to meet the clinical children’s drug needs. We should further increase investments and policy supports for the children’s drugs, promote children’s clinical trials, and encourage the research and development of children’s drugs.